(12) PATENT APPLICATION PUBLICATION
(19) INDIA
(22) Date of filing of Application :25/11/2024

(21) Application No.202411091530 A
(43) Publication Date : 06/12/2024

(54) Title of the invention : SUSTAINED-RELEASE GUANFACINE FORMULATION AND RELATED METHODS

(51) International classification	:A61K0009200000, A61K0031165000, A61K0031155000, A61K0009000000, A61P0029000000
(86) International Application No Filing Date	:NA :NA
(87) International Publication No	: NA
(61) Patent of Addition to Application Number Filing Date	:NA :NA
(62) Divisional to Application Number Filing Date	:NA :NA

(71)**Name of Applicant :**
1)Chitkara University
Address of Applicant :Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura ---------- ----------
2)Chitkara Innovation Incubator Foundation
Name of Applicant : NA
Address of Applicant : NA
(72)**Name of Inventor :**
1)Dr. Sonia Dhiman
Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura ---------- ----------
2)Dr. Thakur Gurjeet Singh
Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura ---------- ----------
3)Vansh Thakur
Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura ---------- ----------
4)Ranvir Singh
Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura ---------- ----------

(57) Abstract :
The sustained-release tablet composition features Guanfacine as an active ingredient, providing controlled-release delivery for extended therapeutic action and reduced dosing frequency. The composition includes a controlled-release matrix formed by hydroxypropyl methylcellulose (HPMC), which extends the release of Guanfacine, ensuring consistent delivery and steady blood levels. Additional components may include lubricants and disintegrant. The method of treating ADHD or hypertension involves administering the tablet once daily, maintaining steady-state plasma concentration over 12 to 24 hours, and reducing side effects associated with immediate-release formulations. The preparation process involves mixing, granulating, drying, and compressing the ingredients to form the tablet. Reference Fig 1

No. of Pages : 14 No. of Claims : 10